Immunomedics, Inc. (IMMU) Q1 2019 Earnings Conference Call May 9, 2019 8:00 AM ET
Company Participants
Chau Cheng - Senior Director, Investor Relations
Behzad Aghazadeh - Executive Chairman
Scott Canute - Executive Director
Usama Malik - Chief Financial Officer
Robert Iannone - Head of R&D and Chief Medical Officer
Conference Call Participants
Maxwell Skor - Morgan Stanley
Paul Choi - Goldman Sachs
Phil Nadeau - Cowen & Company
Chris Howerton - Jefferies
Shanshan Xu - Berenberg Capital
Etzer Darout - Guggenheim
Nick Abbott - Wells Fargo
Joe Catanzaro - Piper Jaffray
Operator
Good morning, ladies and gentlemen, thank you for standing by. As reminder, this call is being recorded today is Thursday, May 9, 2019.
At this time I would like to turn the conference over to Chau Cheng, Senior Director of Investor Relations at Immunomedics.
Chau Cheng
Thank you. Thank you. Before we begin I would like to remind everyone that during this call, we will be making forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements may involve significant risks and uncertainties and therefore actual results could differ materially from those expressed or implied on this call. The factors that could cause such differences please refer to our regulatory filings with the Securities and Exchange Commission.
With us on the call today with prepared remarks are Dr. Behzad Aghazadeh, Executive Chairman; Scott Canute, Executive Director; and Usama Malik, Chief Financial Officer. Also on the call for Q&A is Dr. Robert Iannone. Following prepared remarks, we will open up the call for questions. Thank you. Behzad?
Behzad Aghazadeh
Thank you, Chau. Good morning everyone, and thank you for joining us. I'm pleased to report that we have made significant progress in all business areas during the past three months. As a reminder, I stepped into the role of the
- Read more current IMMU analysis and news
- View all earnings call transcripts